David Fost, MD
Allergy & Immunology · Verona, NJNPI 1356339410
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Genentech USA, Inc. at 35.2% of the total. Reporting peaked in 2023 at $4,851 and has fallen 64.2% since, to $1,736 in 2025.
Across 219 payments — averaging $59.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Pfizer$4K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$873
- Sanofi$614
- GSK$515
- plus $2K from 14 others
Across 16 payments — averaging $2717.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$31K
- AstraZeneca$10K
- Alk-abello, Inc$2K
- Merck$83
What the payments were for
- Consulting fees$3,64528%
- Speaking & faculty fees$3,75029%
- Travel & lodging$7125%
- Food & beverage$4,58935%
- Education$2732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 12 | $4,571 |
| Pfizer | 13 | $3,536 |
| AstraZeneca | 51 | $1,190 |
| Regeneron Healthcare Solutions, Inc. | 39 | $873 |
| Sanofi | 28 | $614 |
| GSK | 26 | $515 |
| Eyevance Pharmaceuticals LLC | 1 | $500 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $323 |
| Optinose US, Inc. | 8 | $245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $165 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Amgen | 5 | $97 |
| Kaleo, Inc. | 3 | $41 |
| Novartis | 2 | $38 |
| Aerin Medical Inc. | 1 | $37 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| LEO Pharma Inc. | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,968 in reported general payments places this provider in the 80th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 87 | $67,755 |
| Dupixent SyringeDupilumab | 17 | $57,543 |
| Dupixent PenDupilumab | 12 | $43,922 |
| XhanceFluticasone Propionate | 44 | $33,959 |
| Arnuity ElliptaFluticasone Furoate | 116 | $32,949 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $27,630 |
| Epinephrine | 71 | $13,611 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $10,733 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $10,713 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $9,458 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,197 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $9,141 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 47 | $8,809 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,737 |
| DuleraMometasone/Formoterol | 12 | $7,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta | $515 | $128,334232 claims |
| Optinose US, Inc.Xhance | $245 | $33,95944 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Pulmicort Flexhaler | $1,190 | $26,85768 claims |
| Hikma Pharmaceuticals USAEpinephrine | $34 | $13,61171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Verona
- Ellen SherOcean$1M
- Peter RickettiTrenton$457K
- John KimMedford$339K
- Tina ZeccaLittle Silver$262K
- George BelecanechVoorhees$208K
- Jacqueline RossOcean$131K
- Shirin JadidiMendham$98K
- Mark WeinsteinBelleville$88K
- Joseph GrizzantiHawthorne$79K
- Lisa BariscianoFlorham Park$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.